Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL701 and Pembrolizumab in mCRPC
NCT03910660Phase 2Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Feb 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of talabostat in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by BioXcel Therapeutics, Inc. Primary endpoints: Composite Response Rate at 36 months and Response Rates at 36 months. Started Feb 2019; status: completed.
02
Drugs
talabostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03910660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910660.